Abhinav A. Shukla - Aug 25, 2025 Form 4 Insider Report for Shattuck Labs, Inc. (STTK)

Role
Chief Technical Officer
Signature
/s/ Andrew R. Neill, Attorney-in-fact for Abhinav A. Shukla
Stock symbol
STTK
Transactions as of
Aug 25, 2025
Transactions value $
$4,444
Form type
4
Date filed
8/27/2025, 06:30 AM
Previous filing
Jan 28, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shukla Abhinav A. Chief Technical Officer C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN /s/ Andrew R. Neill, Attorney-in-fact for Abhinav A. Shukla 2025-08-27 0001923377

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STTK Common Stock Award $4.44K +5.12K +6.73% $0.87 81.3K Aug 25, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STTK Warrants (Right to Buy) Award +5.12K 5.12K Aug 25, 2025 Common Stock 5.12K $1.08 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 5,122 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 5,122 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.
F2 Includes 600 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on February 15, 2025 and 2,000 shares acquired by the Reporting Person under the ESPP on August 15, 2025.
F3 The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.